Literature DB >> 16613917

Development of ocular disease in patients with mucous membrane pemphigoid involving the oral mucosa.

G T Higgins1, R B Allan, R Hall, E A Field, S B Kaye.   

Abstract

AIM: To determine the rate of development of ocular disease in patients presenting with mucous membrane pemphigoid (MMP) involving their oral mucosa.
METHODS: Diagnosis of oral MMP was made on the basis of clinical signs, histology, and direct and indirect immunofluorescence. Age, race, sex, age at diagnosis, progression of eye signs, duration of follow up, and time to progression of ocular disease were recorded.
RESULTS: 30 patients with established oral MMP were reviewed. The mean age at diagnosis was 65.2 years (range 46-84 years) and 16/30 (53%) were male. At initial ocular review nine (30%) patients showed ocular signs of pemphigoid, of whom two had mild (IIA IIIB), four moderate (IIB IIIC), and three severe (IIC IIID) disease. The mean interval between diagnosis of oral MMP and first ophthalmic review was 19.3 months (range 0-144). Over the period of follow up two (7%) patients developed ocular disease at 19 months and 48 months, respectively, despite having had no evidence of ocular involvement at presentation. In total, 11 (37%) patients with oral disease eventually showed ocular disease with a calculated incidence rate for the development of ocular disease of 0.03 per person year over 5 years.
CONCLUSIONS: MMP may affect different tissues at different stages, often separated by many years. Patients with MMP involving their oral mucosa are at significant risk of developing ocular disease and should remain under ophthalmic review.

Entities:  

Mesh:

Year:  2006        PMID: 16613917      PMCID: PMC1857184          DOI: 10.1136/bjo.2006.092528

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  14 in total

1.  Improved detection of disease progression in ocular cicatricial pemphigoid.

Authors:  J Tauber; N Jabbur; C S Foster
Journal:  Cornea       Date:  1992-09       Impact factor: 2.651

2.  Antiepiligrin cicatricial pemphigoid represents an autoimmune response to subunits present in laminin 5 (alpha3beta3gamma2).

Authors:  Z Lazarova; R Hsu; C Yee; K B Yancey
Journal:  Br J Dermatol       Date:  1998-11       Impact factor: 9.302

3.  Cicatricial pemphigoid.

Authors:  C S Foster
Journal:  Trans Am Ophthalmol Soc       Date:  1986

4.  BP180 as the common autoantigen in blistering diseases with different clinical phenotypes.

Authors:  Detlef Zillikens
Journal:  Keio J Med       Date:  2002-03

Review 5.  Acquired skin disease of hemidesmosomes.

Authors:  D Zillikens
Journal:  J Dermatol Sci       Date:  1999-06       Impact factor: 4.563

6.  A retrospective study of the management of oral mucous membrane pemphigoid with dapsone.

Authors:  K N Ciarrocca; M S Greenberg
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod       Date:  1999-08

7.  Immunosuppressive therapy for progressive ocular cicatricial pemphigoid.

Authors:  C S Foster; L A Wilson; M B Ekins
Journal:  Ophthalmology       Date:  1982-04       Impact factor: 12.079

8.  A new method for measuring progression in patients with ocular cicatricial pemphigoid.

Authors:  J James Rowsey; Yolanda Macias-Rodriguez; Chris Cukrowski
Journal:  Arch Ophthalmol       Date:  2004-02

9.  Mucous membrane pemphigoid and pseudopemphigoid.

Authors:  Jennifer E Thorne; Grant J Anhalt; Douglas A Jabs
Journal:  Ophthalmology       Date:  2004-01       Impact factor: 12.079

10.  Incidence and distribution of subepidermal autoimmune bullous skin diseases in three French regions. Bullous Diseases French Study Group.

Authors:  P Bernard; L Vaillant; B Labeille; C Bedane; B Arbeille; J P Denoeux; G Lorette; J M Bonnetblanc; C Prost
Journal:  Arch Dermatol       Date:  1995-01
View more
  7 in total

Review 1.  Subepidermal autoimmune bullous diseases: overview, epidemiology, and associations.

Authors:  Khalaf Kridin
Journal:  Immunol Res       Date:  2018-02       Impact factor: 2.829

2.  Ocular and oral grading of mucous membrane pemphigoid.

Authors:  Graham M B Reeves; Marianne Lloyd; Bijaya P Rajlawat; Gillian L Barker; E Anne Field; Stephen B Kaye
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-11-13       Impact factor: 3.117

3.  Shedding Light on the Trehalose-Enabled Mucopermeation of Nanoparticles with Label-Free Raman Spectroscopy.

Authors:  Soumik Siddhanta; Sourav Bhattacharjee; Sabine M Harrison; Dimitri Scholz; Ishan Barman
Journal:  Small       Date:  2019-07-03       Impact factor: 13.281

Review 4.  [Mucous membrane pemphigoid].

Authors:  M M Holtsche; D Zillikens; E Schmidt
Journal:  Hautarzt       Date:  2018-01       Impact factor: 0.751

5.  Ocular pseudopemphigoid with concomitant eyelid dermatitis secondary to rosacea.

Authors:  Olivia Chukwuma; Sami K Saikaly; Marjorie Montanez-Wiscovich; Caroline Winslow; Kiran Motaparthi
Journal:  JAAD Case Rep       Date:  2020-11-17

6.  Treatment strategies in mucous membrane pemphigoid.

Authors:  Ann G Neff; Matthew Turner; Diya F Mutasim
Journal:  Ther Clin Risk Manag       Date:  2008-06       Impact factor: 2.423

7.  European guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology - Part I.

Authors:  H Rashid; A Lamberts; L Borradori; S Alberti-Violetti; R J Barry; M Caproni; B Carey; M Carrozzo; F Caux; G Cianchini; A Corrà; G F H Diercks; F G Dikkers; G Di Zenzo; C Feliciani; G Geerling; G Genovese; M Hertl; P Joly; A V Marzano; J M Meijer; V Mercadante; D F Murrell; M Ormond; H H Pas; A Patsatsi; C Prost; S Rauz; B D van Rhijn; M Roth; E Schmidt; J Setterfield; G Zambruno; D Zillikens; B Horváth
Journal:  J Eur Acad Dermatol Venereol       Date:  2021-07-10       Impact factor: 6.166

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.